Oncomine Comprehensive Myeloid Panel in UAE – 5,000 AED

Executive Summary & Core Metrics

✔Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing.
✔Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM).
✔Clinical Guidance: Telephonic post‑test clinical guidance for result interpretation.
✔Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The Oncomine Comprehensive Myeloid Panel is a next‑generation sequencing (NGS) test that analyzes DNA and RNA from whole blood or bone marrow aspirate to detect clinically relevant mutations, fusions, and gene expression changes in myeloid malignancies. This panel supports diagnosis, prognosis, and personalized therapy selection for acute myeloid leukemia, myelodysplastic syndromes, and other myeloid neoplasms.

Feature	Our Oncomine Panel	Standard Karyotyping / FISH
Precision	>99.9% analytical sensitivity	60–90% depending on clone size
Methodology	NGS (Next‑Generation Sequencing)	Culture + FISH probes
Speed	Report within 15 days from batch date	7–14 days (often longer)
Gene Coverage	100+ genes & multiple fusion drivers	Limited to a few structural aberrations

Physician Insight & Safety Protocols

“The Oncomine Myeloid Panel delivers deep genomic insight that directly informs targeted therapy decisions for patients with myeloid malignancies. Results must always be correlated with the full clinical picture and interpreted by a qualified specialist.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Medication Advisory

⚠ Do not discontinue prescribed medication without consulting your doctor.

Exclusion Criteria & Emergency Red Flags

Exclusion: Active severe bleeding, inability to provide minimum 2 mL bone marrow or 3 mL whole blood.
Exclusion: Known allergy to local anaesthetic (for bone marrow) without pre‑medication clearance.
Emergency Red Flags: Seek immediate medical attention if you experience uncontrolled bleeding, fever >38°C, severe bone pain, or signs of infection after sample collection.

Patient FAQ & Clinical Guidance

1. What does the Oncomine Comprehensive Myeloid Panel test for?

This panel detects mutations in over 40 genes associated with myeloid malignancies, including FLT3, NPM1, IDH1/2, and BCR‑ABL1, aiding diagnosis, risk stratification, and targeted therapy selection.

2. How is the sample collected and shipped?

A certified phlebotomist collects 3 mL of whole blood in a lavender (EDTA) tube, or a bone marrow aspirate is obtained at a hospital. Samples are shipped refrigerated (never frozen) via cold‑chain logistics for same‑month reporting.

3. Is home collection available in the UAE?

Yes, for whole blood samples our VIP home collection service operates from 8 AM to 11 PM across all Emirates, providing hospital‑grade phlebotomy and immediate cold‑chain transport to our ISO‑certified lab. Bone marrow aspiration must be performed at a hospital.

UAE Regulatory & Data Privacy Adherence

This service complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. Laboratory certified ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). DHA Facility License: 1143.

Clinical & Logistical Metadata

Test Name	Oncomine Comprehensive Myeloid Panel
Price (AED)	5,000
Turnaround Time	15 days from batch date
Sample Type / Matrix	Whole Blood (3 mL EDTA lavender top) or Bone Marrow Aspirate
Methodology Used	Next‑Generation Sequencing (NGS)
ICD‑10‑CM Code	C92.00 (Acute myeloblastic leukemia, not having achieved remission)
LOINC Code	101328-7
DHA Facility License & Laboratory Address	DHA License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE